Nomlabofusp

Human clinical Neuroprotection 3 sources

Nomlabofusp (formerly CTI-1601) is a novel cell-penetrant peptide-based recombinant fusion protein designed as a frataxin replacement therapy. It aims to deliver human frataxin directly into the mitochondria of cells, addressing the underlying deficiency in patients with Friedreich's ataxia.

01Dosing reference

Amount

25 mg or 50 mg (weight-based in trials)

Frequency

Daily for 14 days, then varying maintenance schedules

Cycle

Continuous administration in clinical trial settings

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Cell Penetration

The cell-penetrating peptide portion of the fusion protein allows it to cross cell membranes and enter target cells.

Mitochondrial Delivery

Once inside the cell, the protein is directed to the mitochondria, where it is cleaved to release mature human frataxin.

Frataxin Restoration

Restoring frataxin levels improves mitochondrial function, enhances ATP production, and reduces oxidative stress, potentially modifying the progression of Friedreich's ataxia.

03Human evidence

Increased frataxin levels and improved metabolic function in patients with Friedreich's ataxia.

Phase 2 clinical trials evaluating safety, pharmacokinetics, and pharmacodynamics in adults with FA.

Demonstrated safety and tolerability with dose-dependent increases in frataxin levels in peripheral tissues.

Phase 1 and open-label extension studies in patients with Friedreich's ataxia.

04Preclinical evidence

Successfully delivered functional frataxin to mitochondria, rescuing metabolic defects.

In vitro studies using patient-derived cells and animal models of Friedreich's ataxia.

Improved survival and motor function in severe mouse models of frataxin deficiency.

In vivo studies in frataxin-deficient mouse models.

05What is known vs. unknown

Reasonably established

Nomlabofusp is a recombinant fusion protein utilizing a cell-penetrating peptide to deliver frataxin.
It directly addresses the root cause of Friedreich's ataxia by replacing the deficient frataxin protein.
Clinical trials have shown it can successfully increase frataxin levels in patient tissues.
The FDA has granted it Breakthrough Therapy designation for the treatment of Friedreich's ataxia.

Unknowns & limits

Long-term efficacy and safety in modifying the disease progression of Friedreich's ataxia remain to be fully established in larger Phase 3 trials.
The optimal dosing regimen for sustained frataxin replacement across different age groups, including children, is still under investigation.

06Safety & regulatory context

Regulatory statusNomlabofusp is currently an investigational drug and is not yet FDA-approved for general use, though it has received Breakthrough Therapy, Rare Pediatric Disease, and Fast Track designations from the FDA. In clinical trials, it has generally been well-tolerated, with the most common adverse events being mild to moderate injection site reactions. Long-term safety data is still being collected through ongoing open-label extension studies.

07Compared with Omaveloxolone (Skyclarys)

Nomlabofusp vs. Omaveloxolone (Skyclarys)

Key difference

Omaveloxolone activates the Nrf2 pathway to improve mitochondrial function and reduce oxidative stress, whereas Nomlabofusp is a direct protein replacement therapy that delivers the missing frataxin protein.

When researchers discuss each

Omaveloxolone is discussed as an approved therapy for managing symptoms and slowing progression, while Nomlabofusp is discussed as an investigational disease-modifying approach targeting the root genetic deficiency.

08Glossary

Frataxin

A mitochondrial protein essential for iron-sulfur cluster biogenesis; its deficiency causes Friedreich's ataxia.

Friedreich's ataxia (FA)

A rare, inherited, degenerative disease that damages the spinal cord, peripheral nerves, and cerebellum, leading to impaired muscle coordination.

Cell-penetrating peptide (CPP)

Short peptides that facilitate cellular uptake of various molecular cargo, such as proteins or drugs.

09Knowledge check

Q1What is the primary mechanism of action of Nomlabofusp?

Q2Which component of Nomlabofusp allows it to enter target cells?

Q3Which statement best reflects a documented limitation of the current clinical evidence for Nomlabofusp?

Q4According to the dossier, how does Nomlabofusp’s therapeutic approach primarily differ from Omaveloxolone (Skyclarys)?

Q5Which of the following accurately reflects Nomlabofusp’s regulatory status and commonly reported adverse events in trials, per the dossier?

10Sources

More in Neuroprotection

See all

Cerebrolysin

Neuroprotection

Human clinical

Cerebrolysin is a complex mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research indicates it mimics the action of endogenous neurotrophic factors, promoting neuroprotection, neurogenesis, and synaptic plasticity. It has been extensively studied and utilized in clinical settings for stroke recovery, traumatic brain injury, and neurodegenerative conditions like Alzheimer's disease.

5-50 mL per day depending on the severity of the condition (e.g., 5 mL IM for mild cognitive issues, up to 50 mL IV for acute stroke)

Pinealon

Neuroprotection

Early human

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) designed to act as a peptide bioregulator for the brain and central nervous system. Research suggests it interacts directly with DNA to regulate gene expression, offering neuroprotective effects, improving cognitive function, and reducing oxidative stress in brain cells.

1-2 mg per day (SubQ) or 10-20 mg per day (Oral)

ARA-290 (Cibinetide)

Neuroprotection

Human clinical

ARA-290, also known as Cibinetide, is an engineered peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. Research has primarily focused on its potential to reduce inflammation, promote tissue repair, and alleviate neuropathic pain, particularly in conditions like sarcoidosis and diabetic neuropathy.

4 mg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.